Literature DB >> 21107827

Drug use problems with self-injected low-molecular-weight heparins in primary care.

Seraina Mengiardi1, Dimitrios A Tsakiris, Markus L Lampert, Kurt E Hersberger.   

Abstract

PURPOSE: Outpatient subcutaneous therapies are becoming increasingly common. A literature search failed to find produced any studies on application problems pertaining to the self-injection of low-molecular-weight heparins (LMWH) in a heterogeneous outpatient population under daily-life conditions. We therefore designed a study with the aim of recording drug use problems, patient satisfaction, compliance, problems arising from the injection site (abdomen vs. thigh), and residual drug volumes in pre-filled syringes used in self-injection therapy.
METHODS: Patients were recruited in community pharmacies by 95 trained Master's students in pharmacy. Data were collected during recruitment and by means of structured questionnaire-based telephone interviews that were carried out at the beginning and the end of the LMWH treatment.
RESULTS: The median age of the 213 patients enrolled in the study was 54 years [interquartile range (IQR) 39-70 years]; of these, 15.5% had their injections administered by a third person. The rate of self-reported non-compliance was 17.1%. At least one relevant problem was recorded in 85.0% of the cases. At the end of the treatment, 38.9% of the patients stated self-administration of the injections required some effort. The preferred injection site was the thigh (68.5%). An overall mean residual drug volume ≥ 10.0% was detected for 3.9% of the patients. If residual drug was present, a median of 11.2% (IQR 8.6-17.6%) of the total drug volume had not been injected. Patients injecting into the thigh showed a higher risk of leaving residual medication (odds ratio 2.16, 95% confidence interval 1.04-4.51).
CONCLUSIONS: Most patients had drug use problems, whereas no clear factors were associated with non-compliance, the injection site (apart from residual drug), and discomfort or effort required (apart from prior injection use).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21107827     DOI: 10.1007/s00228-010-0956-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  [What is your diagnosis? Rectus sheath hematoma].

Authors:  F Cuculi; J Gurzeler
Journal:  Praxis (Bern 1994)       Date:  2006-01

2.  Pitfalls in patient self-management of subcutaneous drug application: removal of rubber protection caps from ready-to-use syringes.

Authors:  Seraina Mengiardi; Beat Goepfert; Dimitrios A Tsakiris; Kurt E Hersberger
Journal:  Eur J Clin Pharmacol       Date:  2009-06-18       Impact factor: 2.953

3.  Effects of injection duration on site-pain intensity and bruising associated with subcutaneous heparin.

Authors:  H Chan
Journal:  J Adv Nurs       Date:  2001-09       Impact factor: 3.187

Review 4.  Outpatient treatment of venous thromboembolism using low molecular weight heparins. An overview.

Authors:  M I Matsagas
Journal:  Int Angiol       Date:  2004-12       Impact factor: 2.789

Review 5.  Low-dose heparin. A cause of hematoma of rectus abdominis.

Authors:  N P Tsapatsaris
Journal:  Arch Intern Med       Date:  1991-03

6.  [Hematoma of the rectus muscle of abdomen in a patient treated with nadroparin].

Authors:  Ilaria Pessina; Mario Bocchia; Paolo Giansante; Adriano Vaghi
Journal:  Recenti Prog Med       Date:  2003 Jul-Aug

7.  Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Shannon M Bates; Ian A Greer; Ingrid Pabinger; Shoshanna Sofaer; Jack Hirsh
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

8.  Rectus sheath haematoma associated with low molecular weight heparin: a case series.

Authors:  J Donaldson; C H Knowles; S K Clark; I Renfrew; M D Lobo
Journal:  Ann R Coll Surg Engl       Date:  2007-04       Impact factor: 1.891

9.  The abdomen, thigh, and arm as sites for subcutaneous sodium heparin injections.

Authors:  P S Fahs; M R Kinney
Journal:  Nurs Res       Date:  1991 Jul-Aug       Impact factor: 2.381

10.  Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.

Authors:  Jacob P Lalezari; Indravadan H Patel; Xiaoping Zhang; Albert Dorr; Nina Hawker; Zikia Siddique; Stanley J Kolis; Tosca Kinchelow
Journal:  J Clin Virol       Date:  2003-10       Impact factor: 3.168

View more
  2 in total

Review 1.  Meta-analysis and suggested guidelines for prevention of venous thromboembolism (VTE) in foot and ankle surgery.

Authors:  James D F Calder; Richard Freeman; Erica Domeij-Arverud; C Niek van Dijk; Paul W Ackermann
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-03-18       Impact factor: 4.342

2.  Comparison of modified versus conventional injection techniques of low-molecular-weight heparin in elderly.

Authors:  Wenzhen Geng; Ying Zhang; Juan Shi
Journal:  Pak J Med Sci       Date:  2018 Sep-Oct       Impact factor: 1.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.